Search Results

There are 2536 results for: content related to: The horizon: New targets and new agents

  1. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

    Journal of Viral Hepatitis

    Volume 19, Issue s2, May 2012, Pages: 1–26, I. M. Jacobson, J.-M. Pawlotsky, N. H. Afdhal, G. M. Dusheiko, X. Forns, D. M. Jensen, F. Poordad and J. Schulz

    Version of Record online : 8 MAR 2012, DOI: 10.1111/j.1365-2893.2012.01590.x

  2. You have free access to this content
    HCV Therapeutics: Approved Agents


    Volume 58, Issue S1, October 2013, Pages: 1091A–1168A,

    Version of Record online : 15 OCT 2013, DOI: 10.1002/hep.26880

  3. Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 31, Issue 10, October 2011, Pages: 951–974, Olga M. Klibanov, Shannon H. Williams, Lisa S. Smith, Jacqueline L. Olin and Stephen B. Vickery

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.31.10.951

  4. You have free access to this content
    Review article: specifically targeted anti-viral therapy for hepatitis C – a new era in therapy

    Alimentary Pharmacology & Therapeutics

    Volume 32, Issue 1, July 2010, Pages: 14–28, C. M. Lange, C. Sarrazin and S. Zeuzem

    Version of Record online : 31 MAR 2010, DOI: 10.1111/j.1365-2036.2010.04317.x

  5. You have free access to this content
    AASLD Abstracts


    Volume 56, Issue S1, October 2012, Pages: 191A–1144A,

    Version of Record online : 1 OCT 2012, DOI: 10.1002/hep.26040

  6. You have free access to this content
    Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment


    Volume 55, Issue 4, April 2012, Pages: 1048–1057, Patrick R. Harrington, Wen Zeng and Lisa K. Naeger

    Version of Record online : 1 MAR 2012, DOI: 10.1002/hep.24791

  7. Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans

    Journal of Viral Hepatitis

    Volume 22, Issue 5, May 2015, Pages: 489–495, R. Gidwani, P. G. Barnett, J. D. Goldhaber-Fiebert, S. M. Asch, J. Lo, S. K. Dally and D. K. Owens

    Version of Record online : 24 NOV 2014, DOI: 10.1111/jvh.12344

  8. You have free access to this content
    Poster Sessions


    Volume 58, Issue S1, October 2013, Pages: 92A–207A,

    Version of Record online : 1 OCT 2013, DOI: 10.1002/hep.26726

  9. You have free access to this content
    British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013

    HIV Medicine

    Volume 14, Issue S4, November 2013, Pages: 1–71, Writing Group, Dr Ed Wilkins, Dr Mark Nelson, Dr Kosh Agarwal, Ms Dola Awoyemi, Dr Eleanor Barnes, Dr Sanjay Bhagani, Dr Gary Brook, Dr Ashley Brown, Ms Sheena Castelino, Dr Graham Cooke, Prof Martin Fisher, Prof Anna Maria Geretti, Mr Robert James, Dr Ranjababu Kulasegaram, Prof Clifford Leen, Prof David Mutimer, Dr Chloe Orkin, Dr Emma Page, Dr Adrian Palfreeman, Dr Padmasayee Papineni, Dr Alison Rodger and Dr CY William Tong

    Version of Record online : 25 OCT 2013, DOI: 10.1111/hiv.12106

  10. Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation

    Liver International

    Volume 35, Issue 1, January 2015, Pages: 176–183, Harald Farnik, Tim Zimmermann, Eva Herrmann, Wolf O. Bechstein, Bernd Kronenberger, Peter R. Galle, Sandra Labocha, Nerea Ferreiros, Gerd Geisslinger, Stefan Zeuzem, Christoph Sarrazin and Martin W. Welker

    Version of Record online : 9 APR 2014, DOI: 10.1111/liv.12532

  11. You have free access to this content
    Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

    Liver International

    Volume 32, Issue s1, February 2012, Pages: 54–60, Mitchell L. Shiffman and Rafael Esteban

    Version of Record online : 29 DEC 2011, DOI: 10.1111/j.1478-3231.2011.02718.x

  12. Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1

    Liver International

    Volume 34, Issue 6, July 2014, Pages: 869–889, Dominique Salmon-Ceron, Cédric Arvieux, Marc Bourlière, Patrice Cacoub, Philippe Halfon, Karine Lacombe, Georges-Philippe Pageaux, Gilles Pialoux, Lionel Piroth, Isabelle Poizot-Martin, Eric Rosenthal and Stanislas Pol

    Version of Record online : 25 NOV 2013, DOI: 10.1111/liv.12363

  13. Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant

    Clinical Transplantation

    Volume 28, Issue 6, June 2014, Pages: 722–727, Paul Y. Kwo, Marwan Ghabril, Marco A. Lacerda, Alfred Joseph Tector, Jonathan A. Fridell and Rodrigo Vianna

    Version of Record online : 14 MAY 2014, DOI: 10.1111/ctr.12372

  14. Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations

    The Journal of Clinical Pharmacology

    Volume 55, Issue 5, May 2015, Pages: 517–524, Sandra Bodeau, Eric Nguyen-Khac, Caroline Solas, Youssef Bennis, Dominique Capron, Gilles Duverlie and Etienne Brochot

    Version of Record online : 4 FEB 2015, DOI: 10.1002/jcph.454

  15. Cocrystalline Solids of Telaprevir with Enhanced Oral Absorption

    Journal of Pharmaceutical Sciences

    Volume 104, Issue 10, October 2015, Pages: 3343–3350, Kathy Stavropoulos, Steven C. Johnston, Yuegang Zhang, Bhisetti Govinda Rao, Michael Hurrey, Patricia Hurter, Elizabeth M. Topp and Irina Kadiyala

    Version of Record online : 11 JUN 2015, DOI: 10.1002/jps.24534

  16. You have free access to this content
    Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial


    Volume 56, Issue 6, December 2012, Pages: 2106–2115, Sandra De Meyer, Inge Dierynck, Anne Ghys, Maria Beumont, Bjorn Daems, Ben Van Baelen, James C. Sullivan, Douglas J. Bartels, Tara L. Kieffer, Stefan Zeuzem and Gaston Picchio

    Version of Record online : 4 DEC 2012, DOI: 10.1002/hep.25962

  17. You have free access to this content
    Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis

    Journal of Clinical Pharmacy and Therapeutics

    Volume 39, Issue 1, February 2014, Pages: 14–24, C. Park, S. Jiang and K. A. Lawson

    Version of Record online : 16 NOV 2013, DOI: 10.1111/jcpt.12106

  18. You have full text access to this OnlineOpen article
    Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir

    British Journal of Clinical Pharmacology

    Volume 78, Issue 5, November 2014, Pages: 1043–1049, Mark Johnson, Julie Borland, Shuguang Chen, Paul Savina, Brian Wynne and Stephen Piscitelli

    Version of Record online : 20 OCT 2014, DOI: 10.1111/bcp.12428

  19. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings

    Journal of Viral Hepatitis

    Volume 22, Issue 9, September 2015, Pages: 691–700, A. A. Butt, P. Yan, O. S. Shaikh, M. S. Freiberg, V. Lo Re III, A. C. Justice, K. E. Sherman and for the ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team

    Version of Record online : 18 DEC 2014, DOI: 10.1111/jvh.12375

  20. You have free access to this content
    Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort

    Alimentary Pharmacology & Therapeutics

    Volume 39, Issue 1, January 2014, Pages: 93–103, L. I. Backus, P. S. Belperio, T. A. Shahoumian, R. Cheung and L. A. Mole

    Version of Record online : 10 NOV 2013, DOI: 10.1111/apt.12546